Potential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis

Garima Sharma^1, and D.S. Rathore¹

¹Department of Biotechnology, Govt. Kamla Raje PG (Autonomous) College, Gwalior (M.P.) India

Cite this paper:
Garima Sharma and D.S. Rathore. Potential Role of Nutraceuticals in the Management of Knee and Hip Joint Osteoarthritis. Biomedical Science and Engineering. 2015; 3(1):23-29. doi: 10.12691/bse-3-1-5

Abstract

Nutraceuticals is a broad umbrella term that is used to describe any product derived from food sources with extra health benefits in addition to the basic nutritional value of that food. Over the years nutraceuticals have attracted considerable interest due to their potential nutritional, safe and therapeutic effects in a variety of chronic and life style related diseases like coronary blockage, diabetes and osteoarthritis. Osteoarthritis, better considered as a wear and tear of joint is a result of gradual deterioration of underlying cartilage tissue. The disease results in joint pain, stiffness and its long term effect leads to functional impairment. The current treatment modalities of OA include physical, pharmacological and surgical interventions. Use of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, corticosteroids and hyaluronic injections have proved significantly effective in pain relief and symptomatic management of this disease however their prolonged use have proven side effects on kidney, heart and liver functioning. The surgical methods like total joint arthroscopy, joint debridement, joint irrigation etc. are employed in severe disease state however recovery and post surgical complications are inevitable. In this view focus is being shifted on the use of alternative therapies and nutritional supplements as pain relieving and cartilage protective agents. In the past 3-4 decades significant research has been conducted on the clinical and in vitro testings of nutraceuticals like Glucosamine, Chondroitin sulfate, Hyaluronic acid and others on osteoarthritic subjects and tissues. A large number of dietary supplements are used for a long time for pain relief like cod liver oil for arthritic patients and nowadays as many as one third of suffering populations is using them to improve their clinical condition. The common food sources of these compounds are spinach like leafy vegetables, shark shell, skinned meat etc. Some of the studies have suggested that the efficacy of these nutritional compounds in joint pain relief is equal to non steroidal antiinflammmatory drugs however their onset action is slow. One of the most important limitations associated with their use in treatment of joint related disease is that their clinical efficacy and trials are still lacking. Since nutraceuticals are marketed in a variety of forms like food supplements, injections and powders which have made their effect nonspecific and uncontrollable. In this paper we have covered the results of studies on three well established nutraceuticals (Glucsamine, Chondroitin and Hyaluronic acid) as joint protectors especially in two large weight bearing joints of the body i.e. knee and hip. The results of the studies have indicated that nutraceuticals could represent good alternative means of management of OA however further controlled clinical studies are required for differentiating the effect of purified compound and dose with that of whole food source.

Keywords:
Nutraceuticals Osteoarthritis Chondroitin Glucosamine Hyaluronic acid

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Chaturvedi S., Sharma P.K., Garg V.K. “Role of Nutraceuticals in Health Promotion”. Int J PharmTech Res 3 (1) 442-44, 2011.
[2]	Henrotin Y., Lambert C., Couchourel D., Ripoll C., Chiotelli E. “Nutraceuticals: Do they represent a new era in the management of osteoarthritis?—A narrative review from the lessons taken with five products”. Osteoarthr. Cartilage. 19:1-21, 2011.
[3]	Frech T.M., Clegg D.O. “The utility of nutraceuticals in the treatment of osteoarthritis”. Curr Rheum Rep 9 (1) 25-30, 2007.
[4]	Yelin E “The economics of OA”. In Osteoarthritis. Brandt K.D., Doherty M., Lohmander L.S. (eds) Oxford: Oxford University Press: 17-21, 2003.
[5]	Cheng D.S., Visco C.J. Pharmaceutical therapy for osteoarthritis. PM&R. 2012;4:S82-S88.
[6]	Patrignani P., Tacconelli S., Bruno A., Sostres C., Lanas A. “Managing the adverse effects of nonsteroidal anti-inflammatory drugs”. Exp. Rev. Clin. Pharm. 4,605-21, 2011.
[7]	Guimaraes A.G., Xavier M.A., de Santana M.T., Camargo E.A., Santos C.A., Brito F.A., Barreto E.O., Cavalcanti S.C., Antoniolli A.R., Oliveira R.C. “Carvacrol attenuates mechanical hypernociception and inflammatory response”. Naunyn. Schmiedebergs. Arch. Pharmacol. 385,253-263, 2012.
[8]	Guimaraes A.G., Oliveira G.F., Melo M.S., Cavalcanti S.C., Antoniolli A.R., Bonjardim L.R., Silva F.A., Santos J.P., Rocha R.F.. “Bioassay-guided evaluation of antioxidant and antinociceptive activities of carvacrol.” Basic Clin. Pharmacol. Toxicol. 107, 949-957, 2010.
[9]	Cavalcante Melo F.H., Rios E.R., Rocha N.F., Cito Mdo C., Fernandes M.L., De Sousa D.P., De Vasconcelos S.M., De Sousa F.C. “Antinociceptive activity of carvacrol (5-isopropyl-2-methylphenol) in mice. “ J. Pharm. Pharmacol. 64, 1722-29, 2012.
[10]	Henrotin Y., Clutterbuck A.L., Allaway D., Lodwig E.M., Harris P., Mathy-Hartert M., Shakibaei M., Mobasheri A. “Biological actions of curcumin on articular chondrocytes.” Osteoarth. Cartilage. 18, 141-149, 2010.
[11]	Shen C.L., Smith B.J., Lo D.F., Chyu M.C., Dunn D.M., Chen C.H., Kwun I.S. “Dietary polyphenols and mechanisms of osteoarthritis”. J. Nutr. Biochem. 23, 1367-1377, 2012.
[12]	Daniel J. Leong Marwa Choudhury, David M. Hirsh, John A. Hardin, Neil J. Cobelli, Hui B. Sun. “Nutraceuticals: Potential for Chondroprotection and Molecular Targeting of Osteoarthritis”. Int J Mol Sci. 14(11) 23063-23085, 2013.
[13]	Akhtar N., Haqqi T.M. “Current nutraceuticals in the management of OA: a review” Ther Adv Musculoskelet Dis. 4 (3) 181-207, 2012.
[14]	Jordan K.M., Arden N.K., Doherty M. “EULAR Recommendations 2003: an evidence based approach to the management of knee OA: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials” Ann Rheum Dis 62, 1145-55, 2003.
[15]	Ramsey S.D., Spencer A.C., Topolski T.D., et al. “Use of alternative therapies by older adults with osteoarthritis”. Arthritis Rheum 4, 222-27, 2001.
[16]	Ragle R.L., Sawitzke A.D. “Nutraceuticals in the management of osteoarthritis: a critical review”. Drugs Aging 29 (9), 717-31, 2012.
[17]	Reginster J.Y., Neuprez A., Lecart M.P. “Role of glucosamine in the treatment for osteoarthritis”. . Rheum Int 32 (10) 2959-67, 2012.
[18]	Gupta V.K., Zafer Z.K., Ahmad M. “The Concomitant Consumption of Cod Liver Oil Causes a Reduction in the Daily Diclofenac Sodium Usage in Rheumatoid Arthritis Patients: A Pilot Study”. J Clin Diagn Res 7(7) 1347-51, 2013.
[19]	Cleland L. G., James M. J., Proudman S. M. “Fish Oil: What The Prescriber Needs To Know”. Arth Res and Therapy. 8, 202, 2006.
[20]	James M., Proudman S., Cleland L. “Fish Oil and Rheumatoid Arthritis: Past, Present and Future”. Proc Nutr Soc 69(3), 316-23, 2010.
[21]	National Institutes of Health. Glucosamine sulfate. November 12th 2013.
[22]	National Center for Complementary and Alternative Therapy. Using Dietary Supplements Wisely November 12th 2013.
[23]	Chard J, Lohmander S, Smith C. et al. “Osteoarthritis of the knee”. Clin Evid 14, 1506-22, 2005.
[24]	Clegg D.O. “Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.” New Eng. J. Med 354 (8) 795-808, 2006.
[25]	Felson D.T. “Chondroitin for Pain in Osteoarthritis”. Annal Int. Med. 146: 611-12, 2007.
[26]	Fransen M, Agaliotis M, Nairn L, et al. “Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomized placebo-controlled clinical trial evaluating single and combination regimens”. Annal Rheum Dis 74(5), 851-8, 2015.
[27]	McAlindon T.E., Bannuru R.R., Sullivan M.C “OARSI guidelines for the non-surgical management of knee osteoarthritis”. Osteoarth. Cartil. 22: 363-88, 2014.
[28]	Gouze J.N., Bianchi A., Becuwe P. “Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level and by inhibiting the NF-κB pathway”. FEBS Lett 510, 166-70, 2012.
[29]	Gouze J.N., Gouze E., Popp M.P. “Exogenous glucosamine globally protects chodrocytes from the arthritogenic effects of IL-1β” Arthritis Res Ther. 8, R173, 2006.
[30]	Nakamura H., Shibakawa A., Tanaka M. “Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis”. Clin Exp Rheumatol. 22, 293-99, 2004.
[31]	Uitterlinden E.J., Jahr H., Koevoet J.L. “Glucosamine decreases expression of anabolic and catabolic genes in human OA cartilage explants” Osteoarth. Cartilage. 14, 250-57, 2006.
[32]	Taniguchi S., Ryu J., Seki M. “Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs”. J Orthop Res. 30(5), 673-78, 2011.
[33]	Imagawa K., Andres M.C., Hashimoto K... “The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis”. Biochem Biophys Res Commun 405(3), 362-67, 2011.
[34]	Setnikar I., Palumbo R., Canali S. “Pharmacokinetics of glucosamine in man” Arzneimittelforschung 43 (10), 1109-13, 1993.
[35]	Leffler C.T., Philippi A.F., Leffler S.G.. “Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study”. Mil Med 164 (2), 85-91, 1999.
[36]	Rindone J.P., Hiller D., Collacott E. “Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee”. West J Med. 172(2), 91-4, 2000.
[37]	Dudhia J. “Aggrecan, aging and assembly in articular cartilage”. Cell Mol Life Sci 62 (19-20), 2241-56, 2005.
[38]	Uebelhart D., Malaise M., Marcolongo R. “Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo”. Osteoarth Cartil 12: 269-76, 2004.
[39]	Deal, C.L. “Neutraceuticals as Therapeutic Agents in Osteoarthritis.” Rheumatic Disease Clinics of North America. 25 (2), 379-95, 1999.
[40]	Mazieres B, Combe B, Phan Van A, Tondut J, Grynfeltt M. “Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study”. J Rheumatol 28, 173-81, 2001.
[41]	Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O’Dell J.R., Hooper M.M.l. “Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.” N Engl J Med 354, 795-808, 2006.
[42]	Ronca F., Palmieri L., Panicucci P., Ronca G.. “Anti-inflammatory activity of chondroitin sulfate”. Osteoarthritis Cartilage 6 (Suppl A), 14-21, 1998.
[43]	Chan P.S., Caron J.P., Orth M.W. “Effect of glucosamine and Chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants”. Am J Vet Res 66, 187-6, 2005.
[44]	Orth M.W., Peters T.L., Hawkins J.N. “Inhibition of articular cartilage degradation by glucosamineeHCl and chondroitin sulphate.” Equine Vet J Suppl 224-9, 2002.
[45]	Campo G.M., Avenoso A., Campo S., Ferlazzo A.M., Altavilla D., Calatroni A. “Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats”. Arthritis Res Ther 5:R122-131, 2002.
[46]	Chou M.M., Vergnolle N., McDougall J.J., Wallace J.L., Marty S., Teskey V. “Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis”. Exp Biol Med (Maywood) 230, 255-62, 2005.
[47]	Chan P.S., Caron J.P., Rosa G.J., Orth M.W. “Glucosamine and Chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants”. Osteoarthritis Cartilage 13,387-94, 2005.
[48]	Goto M., Hanyu T., Yoshio T., Matsuno H., Shimizu M., Murata N. “Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial”. Clin Exp Rheumatol 19:377-83, 2001.
[49]	Omata T., Itokazu Y., Inoue N., Segawa Y. “Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis”. Arzneimittelforschung 50, 148-53, 2005.
[50]	Canapp S.O., Jr, McLaughlin R.M., Jr, Hoskinson J.J, Roush J.K., Butine M.D. “Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate”. Am J Vet Res 60, 1552-7, 1999.
[51]	Ronca F., Palmieri L., Panicucci P., Ronca G. “Anti-inflammatory activity of chondroitin sulfate”. Osteoarthritis Cartilage, 6 (Suppl A) 14-21, 1998.
[52]	Verbruggen G., Veys E.M. “Influence of sulphated glycosaminoglycans upon proteoglycan metabolism of the synovial lining cells” Acta Rhumatol Belg, 1 75-92, 1977.
[53]	Nishikawa N., Mori I., Umemoto J. “Influences of sulfated glycosaminoglycans on biosynthesis of hyaluronic acid in rabbit knee synovial membrane”. Arch Biochem Biophys, 240, 146-153, 1985.
[54]	Sawitzke A.D., Shi H., Finco M.F. “The effect of glucosamine and/or CS on the progression of knee OA a report from the glucosamine/chondroitin arthritis intervention trial.” Arthr. Rheum. 58(10), 3183-91, 2008.
[55]	Monfort J., Pelletier J.P., Garcia-Giralt N. “Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues”. Ann Rheum Dis 67(6) 735-40, 2008.
[56]	Sharma G., Saxena R.K., Mishra P. “Synergistic effects of chondroitin sulfate and cyclic pressurization on articular chondrocytes morphology and biochemical properties in alginate matrix”. Osteoarth. Cartil., 16, 1387-1394, 2008.
[57]	Chan P.S., Caron J.P., Orth M.W. “Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions”. Am J Vet Res. 68(7) 709-15, 2007.
[58]	Balazs E. “The physical properties of synovial fluid and the specific role of hyaluronic acid. In Disorders of the Knee. Edited by Helfet AJ. Philadelphia: J B Lippincott; 61-74, 1982.
[59]	Lo G.H., LaValley M., McAlindon T. “Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis”. JAMA 290: 3115-21, 2003.
[60]	Bannuru R.R., Natov N.S., Obadan I.E. “Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee OA: a systematic review and meta-analysis”. Arthri. Rheum 61, 1704-11, 2009.
[61]	Ishijima M., Nakamura T., Shimizu K.. “Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, non-inferiority trial”. Arthritis Res. Therapy 16: R18, 2014.
[62]	Jang J.D., Moon Y.S., Kim Y.S.. “Novel repair technique for articular cartilage defect using a fibrin and hyaluronic acid mixture” Tissue Engg Reg. Med. 10 (1) 1-9, 2013.
[63]	Kim I.R.,Mauck R.L., Burdick J.A. “Hydrogel design for cartilage tissue engineering: A case study with hyaluronic acid” Biomaterials 32, 8771-82, 2011.
[64]	Smith M.M., Ghosh P. “The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment” Rheumatol Int 7: 113-122, 1987.
[65]	Pozo M.A., Balazs E.A., Belmonte C. “Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative”. Exp Brain Res. 116, 3-9, 1997.
[66]	Belmonte C., Pozo M.A., Balazs E.A. “Modulation by hyaluronan and its derivatives (hylans) of sensory nerve activity signaling articular pain. In Chemistry, Biology and Medical Applications of Hyaluronan and Its Derivatives. Proceedings of the Wenner-Gren Foundation International Symposium. Edited by Laurent T. London: Portland Press; 205-217, 1998.
[67]	Kawasaki K., Ochi M., Uchio Y., Adachi N., Matsusaki M. “Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels”. J Cell Physiol 179, 142-8, 1999.
[68]	Ghosh P., Holbert C., Read R., Armstrong S. “Hyaluronic acid (hyaluronan) in experimental osteoarthritis”. J Rheumatol Suppl 43, 155-7, 1995.
[69]	Homandberg G.A., Hui F., Wen C., Kuettner K.E., Williams J.M. “Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: In vitro”. Osteoarthritis Cartilage 5:309-19, 1997.
[70]	Kang Y., Eger W., Koepp H., Williams J.M., Kuettner K.E., Homandberg G.A. “Hyaluronan suppresses fibronectin fragment-mediated damage to human cartilage explant cultures by enhancing proteoglycan synthesis” J Orthop Res 17:858-69, 1999.
[71]	Ogawa Y. “Immunolocalization of stromelysin, tumor factor (TNF) alpha, and TNF receptors in atrophied canine articular cartilage treated with hyaluronic acid and transforming growth factor beta”. Am J Vet Res 57, 1488-96, 1996.
[72]	Yasui T., Akatsuka M., Tobetto K., Umemoto J., Ando T., Yamashita K., Hayakawa T. “Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes”. Biomed Res 13, 343- 8, 1992.
[73]	Nonaka T., Kikuchi H., Shimada W., Itagene H., Ikeda T., Hamanishi C., Tanaka S. “Effects of hyaluronic acid on fibrinolytic factors in the synovial fluid (in vivo). Pathophysiology 6:41-4, 1999(a).
[74]	Tobetto K., Yasui T., Ando T., Hayaishi M., Motohashi N., Shinogi M., Mori I. “Inhibitory effects of hyaluronan on [14C] arachidonic acid release from labeled human synovial fibroblasts”. Jpn J Pharmacol 60, 79-84, 1992.
[75]	Yasui T., Akatsuka M., Tobetto K., Hayaishi M, Ando T. “The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin nE2 production in human osteoarthritic synovial cells”. Agents Actions 37, 155-6, 1999.